Changes
/* Historic Sales */
===Historic Sales===
* Anti-acne products sold through mass retail channels totaled $646 million in The Acne Treatment Manufacturing OTC industry has maintained strong growth during the past five years. From 2007 to account for about 2012, revenue has grown unabated, and it is expected to expand at an average annual rate of 2.4% of all cosmeceutical salesto $2. Subtracting these 3 billion. * Because acne-prone individuals consider treatment products from total sales translates a necessary expense, revenue continued to rise during the recession, though growth from $12did slow as consumers switched to more inexpensive products.4 billion in 2001 In addition, the increasing prevalence of adult-onset and persistent acne conditions has given rise to $15new, targeted products and an expanded consumer base, another factor that has aided revenue growth during the period.6 billion in 2005—still a 6 * . In 2012, industry revenue is expected to maintain its growth, gaining 2.7% CAGRduring the year, due to modest improvements in per capita disposable income.
* The sales figures are of OTC products only and not prescription drugs.
